247 related articles for article (PubMed ID: 36689070)
1. APOC-III: a Gatekeeper in Controlling Triglyceride Metabolism.
Giammanco A; Spina R; Cefalù AB; Averna M
Curr Atheroscler Rep; 2023 Mar; 25(3):67-76. PubMed ID: 36689070
[TBL] [Abstract][Full Text] [Related]
2. Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD.
Taskinen MR; Packard CJ; Borén J
Curr Atheroscler Rep; 2019 May; 21(8):27. PubMed ID: 31111320
[TBL] [Abstract][Full Text] [Related]
3. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor.
Ooi EM; Barrett PH; Chan DC; Watts GF
Clin Sci (Lond); 2008 May; 114(10):611-24. PubMed ID: 18399797
[TBL] [Abstract][Full Text] [Related]
4. APOC-III Antisense Oligonucleotides: A New Option for the Treatment of Hypertriglyceridemia.
Schmitz J; Gouni-Berthold I
Curr Med Chem; 2018; 25(13):1567-1576. PubMed ID: 28595549
[TBL] [Abstract][Full Text] [Related]
5. Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease.
Kohan AB
Curr Opin Endocrinol Diabetes Obes; 2015 Apr; 22(2):119-25. PubMed ID: 25692924
[TBL] [Abstract][Full Text] [Related]
6. The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans.
Borén J; Packard CJ; Taskinen MR
Front Endocrinol (Lausanne); 2020; 11():474. PubMed ID: 32849270
[TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype.
Zheng C; Khoo C; Furtado J; Sacks FM
Circulation; 2010 Apr; 121(15):1722-34. PubMed ID: 20368524
[TBL] [Abstract][Full Text] [Related]
8. Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions.
Zheng C; Khoo C; Ikewaki K; Sacks FM
J Lipid Res; 2007 May; 48(5):1190-203. PubMed ID: 17314277
[TBL] [Abstract][Full Text] [Related]
9. Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics.
Qamar A; Khetarpal SA; Khera AV; Qasim A; Rader DJ; Reilly MP
Arterioscler Thromb Vasc Biol; 2015 Aug; 35(8):1880-8. PubMed ID: 26069232
[TBL] [Abstract][Full Text] [Related]
10. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans.
Graham MJ; Lee RG; Bell TA; Fu W; Mullick AE; Alexander VJ; Singleton W; Viney N; Geary R; Su J; Baker BF; Burkey J; Crooke ST; Crooke RM
Circ Res; 2013 May; 112(11):1479-90. PubMed ID: 23542898
[TBL] [Abstract][Full Text] [Related]
11. Triglyceride-rich lipoprotein metabolism in women: roles of apoC-II and apoC-III.
Ooi EM; Chan DC; Hodson L; Adiels M; Boren J; Karpe F; Fielding BA; Watts GF; Barrett PH
Eur J Clin Invest; 2016 Aug; 46(8):730-6. PubMed ID: 27378472
[TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein C-III: From Pathophysiology to Pharmacology.
Norata GD; Tsimikas S; Pirillo A; Catapano AL
Trends Pharmacol Sci; 2015 Oct; 36(10):675-687. PubMed ID: 26435212
[TBL] [Abstract][Full Text] [Related]
13. Common APOC3 variants are associated with circulating ApoC-III and VLDL cholesterol but not with total apolipoprotein B and coronary artery disease.
Silbernagel G; Scharnagl H; Kleber ME; Hoffmann MM; Delgado G; Stojakovic T; Gary T; Zeng L; Ritsch A; Zewinger S; Speer T; Schunkert H; Landmesser U; März W; Grammer TB
Atherosclerosis; 2020 Oct; 311():84-90. PubMed ID: 32949947
[TBL] [Abstract][Full Text] [Related]
14. ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?
Chan DC; Watts GF
Curr Opin Lipidol; 2024 Jun; 35(3):101-109. PubMed ID: 38372218
[TBL] [Abstract][Full Text] [Related]
15. An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor?
Chan DC; Chen MM; Ooi EM; Watts GF
Int J Clin Pract; 2008 May; 62(5):799-809. PubMed ID: 18201179
[TBL] [Abstract][Full Text] [Related]
16. The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease?
Reeskamp LF; Tromp TR; Stroes ESG
Curr Opin Lipidol; 2020 Jun; 31(3):140-146. PubMed ID: 32324598
[TBL] [Abstract][Full Text] [Related]
17. Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apoC-III transgenic mice.
Aalto-Setälä K; Weinstock PH; Bisgaier CL; Wu L; Smith JD; Breslow JL
J Lipid Res; 1996 Aug; 37(8):1802-11. PubMed ID: 8864964
[TBL] [Abstract][Full Text] [Related]
18. Targeting ApoC-III to Reduce Coronary Disease Risk.
Khetarpal SA; Qamar A; Millar JS; Rader DJ
Curr Atheroscler Rep; 2016 Sep; 18(9):54. PubMed ID: 27443326
[TBL] [Abstract][Full Text] [Related]
19. Metabolic characterisation of disturbances in the APOC3/triglyceride-rich lipoprotein pathway through sample-based recall by genotype.
Corbin LJ; Hughes DA; Chetwynd AJ; Taylor AE; Southam AD; Jankevics A; Weber RJM; Groom A; Dunn WB; Timpson NJ
Metabolomics; 2020 Jun; 16(6):69. PubMed ID: 32494907
[TBL] [Abstract][Full Text] [Related]
20. Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk: The EPIC-Norfolk Prospective Population Study.
van Capelleveen JC; Bernelot Moens SJ; Yang X; Kastelein JJP; Wareham NJ; Zwinderman AH; Stroes ESG; Witztum JL; Hovingh GK; Khaw KT; Boekholdt SM; Tsimikas S
Arterioscler Thromb Vasc Biol; 2017 Jun; 37(6):1206-1212. PubMed ID: 28473441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
